ACR Alpine Capital Research LLC lifted its stake in Express Scripts (NASDAQ:ESRX) by 1.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,820,916 shares of the company’s stock after buying an additional 30,851 shares during the quarter. Express Scripts makes up 6.8% of ACR Alpine Capital Research LLC’s holdings, making the stock its 3rd largest position. ACR Alpine Capital Research LLC owned about 0.32% of Express Scripts worth $125,789,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. SeaCrest Wealth Management LLC purchased a new position in Express Scripts during the fourth quarter worth approximately $105,000. Aevitas Wealth Management Inc. purchased a new position in Express Scripts during the fourth quarter worth approximately $128,000. Financial Gravity Companies Inc. purchased a new position in Express Scripts during the fourth quarter worth approximately $142,000. ClariVest Asset Management LLC boosted its position in Express Scripts by 31,700.0% during the first quarter. ClariVest Asset Management LLC now owns 2,226 shares of the company’s stock worth $153,000 after purchasing an additional 2,219 shares in the last quarter. Finally, Virtue Capital Management LLC purchased a new position in Express Scripts during the fourth quarter worth approximately $176,000. Hedge funds and other institutional investors own 88.20% of the company’s stock.
A number of equities analysts have issued reports on the company. Robert W. Baird set a $92.00 price target on Express Scripts and gave the stock a “buy” rating in a research report on Thursday. BidaskClub downgraded Express Scripts from a “buy” rating to a “hold” rating in a research report on Friday, May 4th. William Blair cut Express Scripts from an “outperform” rating to a “market perform” rating in a report on Thursday, March 8th. Barclays reduced their target price on Express Scripts from $84.00 to $83.00 and set an “equal weight” rating for the company in a report on Thursday, May 3rd. Finally, ValuEngine cut Express Scripts from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. Five equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have given a buy rating to the stock. Express Scripts currently has a consensus rating of “Hold” and a consensus target price of $82.50.
NASDAQ:ESRX opened at $76.35 on Friday. Express Scripts has a one year low of $73.16 and a one year high of $73.65. The company has a quick ratio of 0.56, a current ratio of 0.69 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $41.14 billion, a P/E ratio of 10.75, a P/E/G ratio of 0.92 and a beta of 0.98.
Express Scripts (NASDAQ:ESRX) last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $1.77 EPS for the quarter, beating the consensus estimate of $1.76 by $0.01. Express Scripts had a return on equity of 25.41% and a net margin of 4.59%. The firm had revenue of $24.77 billion during the quarter, compared to analysts’ expectations of $24.80 billion. During the same quarter last year, the firm earned $1.33 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. equities research analysts anticipate that Express Scripts will post 9.09 earnings per share for the current year.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.